New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit Consistent New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit Consistent

The"reassuring" findings from the RE-DUAL PCI study were seen in several subgroups of patients with atrial fibrillation in a setting where they face an excess risk of bleeding with current triple antithrombotic therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news